Generics Lobby Not Fully Sold On FDA Biosimilars Guidance
Generic-drug makers are raising some of the same concerns as brand-name manufacturers regarding the U.S. Food and Drug Administration's recent draft guidance on biosimilars regulation, according to newly released records, raising...To view the full article, register now.
Already a subscriber? Click here to view full article